Ncardia Belgium
47 Rue Adrienne Bolland
6041 Gosselies
Belgium
Services
Products
Applications
close
Pre-clinical studies of drug effects with human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes provide novel possibilities for the assessment of efficient and reliable safety and efficacy drug screenings. Pluricyte® Cardiomyocytes are fully functional hiPSC-derived cardiomyocytes obtained without any genetically modification or purification/selection procedures.
Pluricyte® Cardiomyocytes are cultured in Pluricyte® Cardiomyocyte Medium, a serum free, well-defined culture and maturation medium.
Pluricyte® Cardiomyocytes cultured in Pluricyte® Cardiomyocyte Medium on non-patterned surfaces show a high degree of structural sarcomere organization demonstrating their relatively high level of maturity. (green: alpha actinin, red: myosine heavy chain)
Pluricyte® Cardiomyocytes action potential recordings using manual patch-clamp exhibit a low resting membrane potential (-78 mV), fast upstroke velocity and a well-defined action potential plateau demonstrating a relatively high level of maturity. (Data courtesy of PhysioStim, Lautrec, France).
MEA recordings from Pluricyte® Cardiomyocyte monolayers in response to different doses of hERG channel blocker E4031 demonstrate a concentration-dependent increase in the field potential duration and flattening of the repolarization peak, as expected.
Pluricyte® Cardiomyocytes are ventricular cardiomyocytes differentiated from human-induced pluripotent stem cells without any genetically modification or purification/selection procedures. The cells show highly-organized, aligned sarcomere structures.
First contractions of Pluricyte® Cardiomyocytes appear between 24-48 hours post-thawing. It will take 3-4 days before the cells have formed an electrically coupled monolayer. Stable beating monolayers can be observed 7-8 days post-thawing (15-40 BPM). The optimal time window to perform electrophysiology-based assays with Pluricyte® Cardiomyocytes is between 8-12 days after plating the cardiomyocytes. Due to their relatively low beat rate, Pluricyte® Cardiomyocytes can be easily paced for electrophysiological research.
|
Catalog number |
PCK-1.5 |
|
Production Technology |
Scalable; large lot sizes with minimal batch to batch variation guaranteed by an extensive quality control on identity and functionality |
|
Purity |
>70% based on cardiac Troponin T expression. High purity of ventricular cardiomyocytes based on high MLC2v expression and manual patch clamp |
|
Morphology |
High degree of structural sarcomere organization |
|
Assay window |
Day 8 to 12 post-thaw |
|
Single cell action potential |
Low resting membrane potential (~-78 mV), fast upstroke velocity, |
|
Monolayer field potential |
Well-pronounced and robust de- and repolarization peaks, |
|
Recommended Storage |
Pluricyte® Cardiomyocyte Medium: -20°C, after opening store at 2-8°C for a maximum of 14 days, no freeze-thaw cycles recommended Pluricyte® Cardiomyocytes: liquid nitrogen vapor phase |
SOT 2017: Assessment of electrophysiology, contractility and viability effects of three UCB compounds on human induced pluripotent stem cell-derived (hiPSC) cardiomyocytes using the Real Time Cell Analyzer (RTCA) CardioECR platform – In collaboration with UCB Biopharma
SOT 2017: Towards prediction of acute and chronic drug effects using multi-parameter profiling of hiPSC-derived cardiomyocytes.